NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck

 
• By Joseph Haas
  
Crash & Burn
NGM's stock price declined by 70% after the CATALINA data were unveiled • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D